Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Ltd. has reported significant progress in its clinical trials, with promising early results from its CHM CORE-NK trial at MD Anderson Cancer Center, showing complete remission in two out of three AML patients. The company is also advancing its CHM CDH17 CAR-T program, having safely progressed to a higher dose level without dose-limiting toxicities, and is well-funded to continue its trials. Financially, Chimeric has strengthened its position through non-dilutive funding and successful capital raises, positioning it to prioritize clinical development and data generation.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of cell therapies for cancer treatment. The company is involved in clinical trials for its innovative therapies, including CHM CORE-NK and CHM CDH17 CAR-T, targeting conditions like acute myeloid leukemia (AML) and glioblastoma. Chimeric leverages partnerships with institutions like MD Anderson Cancer Center and Case Western Reserve University to advance its research and development efforts.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.4M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.